Drug intelligence / Profile preview

PECS-111

Development stage: Preclinical
Lead developer: Phytecs
Modality: Small Molecules

Overview

PECS-111 is a preclinical-stage small molecule developed by Phytecs Pharm. It is a fluorinated derivative of cannabidiol (F-CBD) designed to modulate the endocannabinoid system (ECS). Preclinical studies suggest that PECS-111 exhibits significantly greater potency compared to natural CBD. The compound is being investigated for a wide range of therapeutic applications, including neuropsychiatric disorders such as anxiety, psychosis, obsessive-compulsive disorder (OCD), and schizophrenia, as well as epilepsy, chronic pain, and various inflammatory skin conditions like dermatitis, psoriasis, and acne. The development of PECS-111 involves collaborations with several academic and research institutions, including the University of São Paulo and the European Brain Research Institute.

Other names: fluorinated cannabidiol derivativeF-CBD derivative

Beyond the preview

Go deeper on PECS-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PECS-111.

Explore the full profile